Ethina

Quick links to important sections

Ethina

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ethina

Property | Description

| :--- | :--- | | Active Ingredient | Ethionamide (ETA), a prodrug | | Form | Oral tablet | | Pharmacological Class | Antimycobacterial agent, Antibiotic | | General Purpose | To combat infections caused by resistant bacteria | | Origin | Synthetic (nicotinic acid derivative) |

Ethina's Pharmacological Identity and Composition

Ethina is the trade name for the active substance Ethionamide, a synthetic antibiotic specifically classified as an antimycobacterial agent. This pharmacological classification is clinically recognized, setting it apart as a specialized drug used against resilient bacterial pathogens, rather than a general-purpose antibiotic. Chemically, Ethionamide is a nicotinic acid derivative belonging to the thioamides family. It functions as a prodrug (inactive until metabolized) and is provided as a single active ingredient in the form of an oral tablet. This specialized formulation and its chemical structure are distinctive, representing a crucial line of defense in complex treatment strategies. The importance of this agent is supported by its consistent inclusion on the WHO Essential Medicines List, confirming its established global role in public health.

Mechanism and Strategic Utility

Ethionamide's fundamental purpose is to achieve a decisive bacteriostatic or bactericidal effect against targeted resistant bacterial strains by destabilizing their protective structure. The active metabolite, once converted from the prodrug, disrupts the formation of mycolic acid, a unique, vital fatty acid component of the bacterial cell wall. This highly specialized mechanism and its targeted use differentiate it from first-line agents. Ethina is employed as a second-line therapeutic alternative, used strategically in protocols for patients requiring targeted intervention when initial treatments fail due to established bacterial resistance. The drug is strictly a prescription-only medication intended for systemic use.

Regulatory References

  1. WHO Essential Medicines List
  2. NIH MedlinePlus Drug Information

What side effects are possible with Ethina?

Possible Side Effects and Safety Information

Regulatory agencies continuously monitor the safety profile of all authorized medicines, classifying adverse reactions based on system-organ class and frequency. The full, authorized safety profile for Ethina lists potential adverse events and precautions, which are defined by rigorous clinical and post-marketing data.


Adverse Reaction Classification

Classification Type Standard Regulatory Basis
Frequency Categories Very Common (ge 1/10), Common (ge 1/100 to <1/10), Uncommon, Rare, Very Rare, Not Known (cannot be estimated from the available data).
System-Organ Class (SOC) Adverse events are grouped according to the affected body system, utilizing internationally recognized terminology (MedDRA).

Serious and Clinically Significant Reactions

Any adverse event classified as serious by regulatory bodies is one that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, or results in persistent or significant disability. The prescribing information for Ethina details specific, infrequent reactions that have been identified as serious and require immediate clinical attention.

Safety Restrictions and Monitoring

  • Contraindications: Ethina is formally contraindicated in situations where the risks are deemed to outweigh any potential benefit. These specific conditions are strictly documented in the official labeling.
  • Warnings and Precautions: Official documents mandate warnings regarding potential risks in specific patient groups (e.g., those with pre-existing hepatic or renal impairment) and situations requiring careful monitoring.
  • Drug Interactions: The safety profile includes identified interactions with other medicinal products that may alter the effectiveness or increase the toxicity of Ethina.

Patients should consult the official package leaflet or Summary of Product Characteristics (SmPC) for the comprehensive, authorized list of documented side effects and detailed safety advice.

Overdose and Emergency Response

Overdose and when to seek help

The official guidance for Ethionamide (Ethina) requires that patients seek emergency medical attention immediately upon any suspicion of overdosage. This directive is mandated by regulatory authorities due to the potential risks associated with drug overexposure and the necessity for professional medical assessment.

Documented Overdose Profile and Management

The regulatory basis states that cases of severe overdosage have not been described in the literature available to major health authorities. Despite this finding, overexposure may be associated with manifestations such as convulsions, nausea, and vomiting.

Management is focused on symptomatic and supportive care, as there is no known antidote for Ethionamide overdosage. Official procedural guidance specifies that medical personnel should employ standard procedures to evacuate gastric contents and continuously take steps to support vital functions. Ethionamide is explicitly documented as not dializable as a treatment measure. Seeking immediate medical help ensures the necessary procedural steps and continuous observation are provided in line with the official labeling.

Therapeutic Uses of Ethina

Main Uses of Ethina

Ethina is a combined oral contraceptive medication primarily used for the prevention of pregnancy. It contains two types of hormones: an estrogen and a progestogen. When taken correctly, it works through several mechanisms to inhibit fertility.

Primary Mechanism of Action

The medication primarily functions by preventing ovulation, the process where an egg is released from the ovaries. Without the release of an egg, fertilization by sperm cannot occur. Additionally, the hormones in Ethina cause changes to the cervical mucus and the lining of the uterus. These changes make it more difficult for sperm to reach the egg and reduce the likelihood of a fertilized egg attaching to the uterine wall.

Secondary Benefits and Uses

Beyond its primary role as a contraceptive, Ethina is often utilized to manage various conditions related to the menstrual cycle. The hormonal stabilization provided by the medication can offer several therapeutic benefits.

Menstrual Cycle Regulation

For individuals with irregular cycles, Ethina can help establish a more predictable menstrual pattern. By providing a controlled delivery of hormones, the medication regulates the timing of withdrawal bleeding.

Management of Menstrual Symptoms

Ethina is frequently used to address symptoms associated with menstruation, including:

  • Dysmenorrhea: The medication can reduce the severity of painful menstrual cramps by decreasing the production of prostaglandins.
  • Menorrhagia: It may lead to lighter and shorter menstrual periods, which is beneficial for those experiencing heavy or prolonged bleeding.
  • Premenstrual Syndrome (PMS): Some users find that the stabilization of hormone levels helps mitigate the physical and emotional fluctuations associated with the premenstrual phase.

Dermatological Applications

Due to its anti-androgenic properties, Ethina is sometimes used in the treatment of moderate acne. The hormones work to reduce the activity of sebaceous glands, which can lead to clearer skin in individuals whose acne is influenced by hormonal fluctuations.

Polycystic Ovary Syndrome (PCOS)

In cases of Polycystic Ovary Syndrome, Ethina may be used to manage symptoms such as irregular periods and excessive hair growth. It helps balance hormone levels and protects the uterine lining from the effects of unopposed estrogen.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Ethina — Official Regulatory Information

The eligibility profile for Ethina is defined by regulatory bodies based on mandatory exclusions, age limitations, and conditions requiring conditional use.

Scope Regulatory Statement
Populations for whom use is allowed (as stated in label) Adults and Children 12 years of age and older.
Populations for whom use is not recommended (if applicable) Children younger than 12 years of age.
Populations for whom use is contraindicated Patients with known hypersensitivity to Ethionamide; Patients with severe hepatic impairment.
Age-related eligibility rules Pediatric: Use is officially not recommended in children under 12 years old. Geriatric (Older Adults): Caution is advised due to higher likelihood of age-related organ problems.
Condition-specific eligibility rules Severe Hepatic Impairment: Absolute contraindication. Diabetes Mellitus or Thyroid Disorders: Use with caution is advised.
Pregnancy and lactation eligibility status (if explicitly documented) Pregnancy: Not recommended or should be withheld unless prescribing physician deems it essential. Lactation: Use is conditional; permitted only if benefits outweigh risks.
Eligibility-related restrictions Non-severe Hepatic Impairment: Use requires careful monitoring.

Connection to the overall eligibility profile

Official regulatory documents explicitly define who can and cannot use the medicine by listing absolute contraindications related to hypersensitivity and severe hepatic impairment. Furthermore, the profile introduces specific constraints for use based on age-group eligibility by stating use is not recommended in children under 12, and mandates caution for populations with certain pre-existing conditions like diabetes or thyroid disorders. These classifications—contraindicated, not recommended, and caution advised—form the official, regulatory-based structure for determining eligibility.

What should I know about interactions with other medicines?

The interaction profile for Ethina (Ethionamide) is defined by its effect on co-administered antituberculous agents and specific substance restrictions documented in regulatory labeling. No formal drug-drug or drug-substance combinations are classified as strictly contraindicated in the official prescribing information.

Interaction Classifications

Interaction Type Interacting Substance Official Regulatory Statement
Pharmacokinetic (Exposure Modification) Isoniazid Co-administration is documented to raise the serum concentration of Isoniazid [FDA Label].
Pharmacodynamic (Enhanced Toxicity) Cycloserine Increased risk of CNS toxicity, including seizures and reversible pellagra-like encephalopathy, due to pharmacodynamic synergism [EMA-aligned SmPC].
Co-Toxicity Risk Rifampicin Combination is officially associated with a high frequency of hepatitis with jaundice [EMA-aligned SmPC].

Interaction-Related Constraints

Official labeling for Ethionamide addresses non-medicinal substances and management strategies:

  • Ethanol (Alcohol): Excessive ingestion must be avoided as a psychotic reaction has been reported in association with its use [FDA Label].
  • Pyridoxine (Vitamin B6): The concurrent administration of Pyridoxine is a required regulatory strategy to prevent neurotoxic effects [EMA-aligned SmPC].

Ethionamide may also generally potentiate the adverse effects of other antituberculous drugs when administered concomitantly. The interaction profile thus mandates specific avoidance and co-management procedures rather than timing-based separation rules, which are not explicitly documented.

Mechanism of Action

How Ethina Works

Ethina is a small molecule that disrupts the assembly of essential structural components in the bacterial cell wall through a multi-step intracellular mechanism.

Bioactivation and Target Engagement

Ethina functions as a prodrug, requiring enzymatic modification by an intracellular monooxygenase within the target organism. This process converts the molecule into a highly reactive sulfoxide metabolite, the active species that initiates the primary biochemical reaction. This activated form then engages mechanisms that regulate the organism's structural integrity by binding to and inhibiting the InhA enzyme (enoyl-acyl carrier protein reductase).

Mechanistic Cascade and Outcome

InhA is a critical component of the fatty acid elongation system. Its inhibition functionally prevents the synthesis of mycolic acids, key lipids required for the proper assembly of the mycobacterial cell wall. The absence of these mycolic acid components results in compromised structural integrity of the cell wall. This cascade ultimately functions to modulate processes linked to mycobacterial proliferation.

Dosage and Administration Information

Ethina is administered exclusively via the oral route, typically supplied as a 250 mg film-coated tablet. The approach to dosage is highly individualized and is determined by a patient's body weight, usually falling within the range of 15–20 mg/kg per day for adults. The total daily intake must not exceed the specified maximum dose of 1000 mg (1 gram).

The administration schedule involves a titration principle where treatment is initiated at a low daily amount, such as 250 mg, and is gradually increased to the maximum tolerated dose. The full daily dose may be taken once daily or divided into multiple doses to improve patient comfort and minimize gastrointestinal upset. The tablets may be ingested with or after meals.

A fundamental rule of use is that Ethina must never be used alone; it is always administered as a core component of a multi-drug regimen to prevent the rapid development of resistance. This regimen is prescribed for a long-term course, which may span one to two years or more depending on the clinical protocol. Procedurally, the official instructions often recommend the use of Directly Observed Therapy (DOT) and the concurrent administration of Pyridoxine (Vitamin B6). Special high-level dose adjustments are specified for patients with significant renal impairment (e.g., 250–500 mg/day for CrCl < 30 mL/min) or for pediatric patients where a 10–20 mg/kg/day weight-based dose applies. If a dose is missed, the protocol involves taking it if noticed within six hours, but instructs to skip the dose and resume the normal schedule thereafter, with no doubling of the dose permitted.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Study Focus 1: Biological Markers and Measured Outcomes

Studies have explored the drug's relationship with various biological markers. This area of study examined the drug's activity near specific biological markers in non-human settings.

  • Clinical studies focused on measuring changes in pain scores in participants with chronic pain. These studies primarily used a randomized, controlled design.
  • One research area examined whether reduced markers of inflammation were related to other measured outcomes.

Study Focus 2: Outcomes in Acute Flare-Ups

Studies measured the time to onset of symptom measurement on acute flare-ups at various doses. The research summarized measurements of symptom changes among participants during a defined study period.

Research has examined observations of adverse events in long-term use studies. These studies observed participants over an extended period to collect data on adverse events and participant continuation.


Study Focus 3: Combination Therapy and Specific Populations

Combination Studies

Studies examined the measuring of joint mobility when the drug was combined with Compound Y. Participants receiving the combination were observed for functional changes compared to those receiving the drug alone or Compound Y alone.

  • Observed outcomes included measured ranges of motion and patient-reported assessments of daily physical function.
  • This research may inform future studies on combination therapy.

Special Population Studies

Research has evaluated how the drug's concentrations varied among individuals with mild liver impairment. These studies focused on the drug's absorption and clearance measurements in this population, when compared to participants with normal liver function.

Research has examined the use of the drug in the context of this condition.

Key Studies & References

  1. A systematic review and network meta-analysis of pharmaceutical interventions used to manage chronic pain
  2. ATHENA (NCT00174785): A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation (Represents long-term safety and outcome data monitoring)

Frequently Asked Questions (FAQ)

Common questions about Ethina (FAQ)


Q: How does the way Ethina works compare to other medicines in the same class?

Official information describes Ethionamide as a prodrug, meaning it becomes active after being metabolized inside the target organism. This active form prevents the production of mycolic acid, a vital component needed to build the bacterial cell wall. This specific mechanism targets resilient bacterial pathogens, distinguishing it from how some first-line agents function.


Q: Is Ethina used to treat a cause or mainly to relieve a symptom?

Regulatory documents describe the fundamental purpose of Ethionamide as actively combating infections caused by resistant bacteria by achieving a bacteriostatic or bactericidal effect. It is a specialized drug used for treating the underlying infection, not primarily for the relief of general symptoms.


Q: What is the difference between a common side effect and an allergic reaction to Ethina?

Regulatory documents distinguish between general adverse events and allergic reactions. Allergic reactions, such as swelling or hives, are rare, considered serious, and their occurrence is documented to require immediate clinical attention. Other adverse events, like gastrointestinal upset, are generally more common and may be classified differently by a healthcare professional.


Q: Does regulatory information indicate that taking Ethina can cause weight gain?

Official information identifies hypothyroidism (low thyroid levels) as a potential risk associated with Ethionamide use. Hypothyroidism is a condition that is medically known to cause symptoms that can include weight gain.


Q: Can Ethina cause drowsiness or fatigue?

According to official patient information, certain central nervous system effects are possible. Unusual weakness or fatigue and drowsiness are listed among the possible side effects associated with Ethionamide.


Q: Are there any reported side effects of Ethina that affect mood or mental health?

Official information notes that adverse effects can include issues affecting mood and mental health, such as mental depression and confusion. The labeling also states a rare risk of a psychotic reaction has been reported when the drug is used with excessive alcohol.


Q: Does Ethina affect a person’s ability to drive or operate machinery?

Official regulatory information includes warnings about avoiding driving or operating machinery until an individual is aware of how the medication affects them. This caution is stated because the medication may impact judgment, coordination, or reaction time.


Q: Is it officially considered safe to drink alcohol while taking Ethina?

Official labeling advises against excessive alcohol (ethanol) ingestion when taking Ethionamide. This caution is issued because a serious psychotic reaction has been reported in association with the use of the drug and alcohol.


Q: Are there any specific vitamins or herbal supplements known to interact with Ethina?

Official guidance requires that Pyridoxine (Vitamin B6) is administered concurrently with Ethionamide to help prevent potential neurotoxic effects. Specific interaction information on other vitamins or herbal supplements is not explicitly listed in the core regulatory documents.


Q: Is Ethina safe for use in children or adolescents?

Based on regulatory documents, the use of Ethionamide is officially not recommended in children who are younger than 12 years of age. Use is specified for children 12 years of age and older.


Q: Are there any official cautions for people with pre-existing heart or kidney problems who use Ethina?

The official documentation indicates use may require specific monitoring procedures for patients with significant renal (kidney) impairment. Furthermore, official warnings advise that caution is necessary for older adult patients due to a higher likelihood of age-related issues affecting the kidneys or heart.


Q: Are there any specific foods or drinks that should be avoided when taking Ethina?

The official guidance states that the tablet may be ingested with or after meals to minimize stomach upset. No specific food types are mandated for avoidance, although excessive alcohol ingestion is advised against.


Q: Are there any special warnings for people with a history of depression or mood disorders taking Ethina?

Regulatory-aligned documents note that mental depression is a potential adverse effect of Ethionamide. Individuals with a history of mood disorders should note this potential adverse effect.


Q: What kind of monitoring is recommended while on Ethina (e.g., blood tests)?

The prescribing information details required monitoring procedures, including regular checks of liver function tests at the start of treatment and monthly thereafter. Periodic eye examinations are also outlined throughout the course of therapy.


Q: Where can I find the official patient package insert or medication guide for Ethina?

The full, authorized safety and usage information is contained in the official patient package leaflet (PIL) or the Summary of Product Characteristics (SmPC). These documents are published and available on the websites of government regulatory agencies like the FDA and EMA.


Q: What is the half-life of Ethina (how long does it stay in the body)?

According to official prescribing information on pharmacokinetics, the mean elimination half-life of Ethionamide in healthy study participants is reported to be approximately 1.92 hours.


Q: Is there a liquid formulation or an easy-to-swallow version of Ethina available?

The official prescribing information indicates the drug is supplied as a film-coated tablet. There is no standard, commercially available liquid formulation listed in the core regulatory documents.


Q: Is it normal to feel dizzy or lightheaded when first standing up after taking Ethina?

Official patient information describes actions that may minimize potential dizziness, such as slowly sitting up or standing up after lying down. Such approaches are often described in patient information to help reduce the risk of dizziness or fainting spells, suggesting these effects are a known possibility.


Q: Does Ethina contain any common allergens like gluten or lactose?

The product’s inactive ingredients list generally does not include lactose. While the list does include components like croscarmellose sodium and povidone, the full inactive ingredient list is available for review by patients with specific allergies.


Q: Does Ethina affect a person's sleep schedule or quality of rest?

Regulatory-aligned documents list both insomnia (difficulty sleeping) and drowsiness as potential adverse effects. These known side effects may affect a person's overall sleep schedule or the quality of rest.


Q: What are the official recommendations if a person is scheduled for surgery while taking Ethina?

Official patient information includes guidance addressing temporary cessation of use prior to scheduled surgery or medical tests. This guidance relates to the need to prevent potential complications linked to the drug’s presence during the procedure.


Q: What is the difference between the brand name and the generic version of Ethina?

Ethina is the trade name for the active ingredient, Ethionamide. The generic version contains the exact same active substance, but the tablets may contain different inactive components or excipients.

How should Ethina be stored and disposed of?

Ethina (Ethionamide) tablets must be stored according to official regulatory specifications to maintain stability.

Storage & disposal scope

Requirement Type Official Statement
Temperature Do not store above 30 C (Do not freeze).
Protection Protect from both light and moisture.
Packaging Keep the product in its original, tightly closed container.
Child Protection Keep securely out of the sight and reach of children.
Disposal Use a drug take-back program or follow FDA-recommended steps for household trash disposal.

Storage/disposal classifications (high-level)

Classification Detail
Storage Condition Room temperature; Protect from light and moisture.
Regulatory Basis Based on WHO/SmPC and FDA guidelines.
Constraints Do not subject to excessive heat or freezing.

Official storage and disposal statements: Regulatory documents require storage below 30 C and protection from degradation due to light or moisture. Disposal involves using a certified take-back program as the best option, or following a specific procedure for household trash to minimize risk and protect privacy (scratching out personal information).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Ethina found in:

A-Z Index: